ACTRN12622001137785尚未招募未知
Observational Study of the Safety, Tolerability and Efficacy of Cannabidiol Oro-buccal Sprays for Treating Pain and/or Stress
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •1.Patients who have been prescribed MC-1020 or MC-1023 for pain and/or stress.
- •2.Prospective participants greater than or equal to 18 years of age at the time of entry on study;
- •3.Prospective participants have the cognitive ability to understand the informed consent process and to give informed consent to participate in the observational study;
- •4.Prospective participants are eligible to be lawfully prescribed MC-1020 or MC-1023 by the Participating Doctor;
- •5.Prospective participants are able to visit their Participating Doctor’s and Participating Pharmacist’s clinics as required while being treated MC-1020 or MC-1023 and are able to provide information as required for the duration of the study;
- •6.Prospective participants agree to abstain from using any cannabis products other than MC-1020 or MC-1023 for the duration of their participation in the study.
排除标准
- •1.Prospective participants will be ineligible if they are under the age of 18 years;
- •2.Prospective participants will be ineligible if they are unwilling or unable to sign the Informed Consent Forms or cannot understand the Participant Information Sheet provided;
- •3.Prospective participants will be ineligible if they have a hypersensitivity to cannabinoids or to any of the study treatment excipients;
- •4.Pregnant or lactating women;
- •5.Prospective participants judged by the Principal Investigator to be ineligible for participation as study participants for any reason;
- •6.Prospective participants will be ineligible if they are unwilling or unable to perform study procedures as described in the study protocol.
- •7.Prospective participants will be ineligible if they have concurrent medicinal or recreational cannabinoid use.
研究者
相似试验
尚未招募
不适用
Observational Study of the Safety, Tolerability and Efficacy of cannabis-based medicineChronic PainCancer - Any cancerInflammatory and Immune System - Rheumatoid arthritisInjuries and Accidents - Other injuries and accidentsMusculoskeletal - Other muscular and skeletal disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonPublic Health - Other public healthACTRN12622001133729Medlab Clinical Ltd1,000
进行中（未招募）
1 期
A study evaluating the efficacy, safety and tolerability of Nangibotide in patients with Covid-19.Covid-19MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001504-42-FRINOTREM S.A.60
尚未招募
1 期
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part AChronic Myeloid Leukaemia (CML)Parkinson's Disease (PD)Cancer - Leukaemia - Chronic leukaemiaNeurological - Parkinson's diseaseACTRN12624000115538Enliven Therapeutics, Inc.15
尚未招募
1 期
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part BChronic Myeloid Leukaemia (CML)Parkinson's Disease (PD)Cancer - Leukaemia - Chronic leukaemiaNeurological - Parkinson's diseaseACTRN12624000116527Enliven Therapeutics, Inc.15
进行中（未招募）
1 期
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaMaintenance treatment of schizophrenia in patients currently treated with oral antipsychoticsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2019-000063-24-FRTeva Branded Pharmaceutical Products R&D, Inc.300